XOFLUZA (Roche Products Pty Ltd)
Product name
XOFLUZA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
226 (255 working days)
Active ingredients
baloxavir marboxil
Registration type
EOI
Indication
Prophylaxis of influenza
XOFLUZA (tablet) is now also indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.
Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.